products

C37H48N6O5S2 Pneumonia Treatment Drugs Ritonavir CAS 155213-67-5 720.96 Molecular Weight

Basic Information
Place of Origin: CHINA
Brand Name: MOSINTER
Certification: COA
Model Number: Pneumonia Treatment Drugs - 7
Minimum Order Quantity: 25KGS
Price: Negotiation
Packaging Details: Aluminum foil bag , fiber can , kraft paper bag , plastic drum , 1kg/ bag or 25kg/ drum or as required
Delivery Time: Within 7 days
Payment Terms: T/T, Western Union
Supply Ability: 200-300 MTS/month
Detail Information
Name: Ritonavir CAS: 155213-67-5
Form: Powder Molecular Formula: C37H48N6O5S2
Molecular Weight: 720.96 Type: Pneumonia Treatment Drugs
High Light:

anti pneumonia drugs

,

chloroquine diphosphate


Product Description

Ritonavir CAS 155213-67-5 Pneumonia Treatment Drugs

 

Description:

 

Lopinavir / ritonavir have been listed in China for a long time and are mainly used in the treatment of AIDS. The main drug of lopinavir is to combine with virus protease to make the virus particles produced immature and non infectious; while ritonavir can inhibit the metabolism of lopinavir in liver, thus improving the blood concentration of lopinavir and playing a synergistic role.

 

Specifications:

 

Items Specifications Results
Appearance White to off-white powder White powder
Residue on ignition NMT 0.2% 0.10%
Heavy metals NMT 20 ppm Conforms
Sulphated ash NMT 0.105 0.03%
Assay (by HPLC) 98.0%~102.0% 99.00%

 

Related products:CAS 192725-17-0


Application:

 

This product is suitable for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and children over 2 years old with other antiretroviral drugs.

The experience of using lopinavir and tonavir is mainly from patients who have not received antiretroviral therapy. Data on patients who have been treated with protease inhibitors are very limited. There are also very limited data on remedial treatment in the case of failure of lopinavir.

Whether HIV-1 patients who have been treated with protease inhibitors choose this drug or not depends on two factors: the results of individual virus resistance test and the treatment history.

The novel coronavirus pneumonia treatment plan (trial version third) was released in January 22, 2020, and patients can be treated with R-B or ritonavir.

 

Our strengths:

 

We can customize according to customer's requirement.

If you have any question pls mail us or call us.

 

Contact Details
Fedor

Phone Number : +86 18989305995

WhatsApp : +18989305995